We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




New Stent Uses Revolutionary Biomaterial

By HospiMedica staff writers
Posted on 31 Oct 2007
A revolutionary new biomaterial is being used to develop biodegradable stents for use in cardiac surgery.

Researchers at the New Jersey Center for Biomaterials (NJCBM, Piscataway, USA) at Rutgers University (Newark, NJ, USA) developed a library of degradable polymers comprising 10,000 theoretically possible compositions and applied combinatorial methods to identify the best possible biomaterial for the new stent. More...
The resulting biodegradable, biocompatible polymer is exceptionally strong and highly suitable for stent applications. In addition, the material was designed to be radio-opaque, a property critical to the proper placement of the stent in the artery.

The new stent based on the polymer's specifications is being designed and tested by REVA Medical (San Diego, CA, USA), and is intended to act as a temporary scaffold to support the blood vessel during the healing process and maintain blood flow. It subsequently dissolves, leaving the patient free of any permanent implant. The REVA Endovascular Study of a Bioresorbable Coronary Stent (RESORB) trial is evaluating the stents safety in approximately 30 patients at multiple sites in Germany and Brazil.

"Our unconventional discovery process integrates combinatorial polymer libraries, high-throughput testing, and computational modeling. This results in a much faster path to prototype development and a reduction in the cost and risk associated with the use of new, proprietary biomaterials,” said lead investigator Professor Joachim Kohn, director of the NJCBM.

RESORB is a non-randomized study of the resorbable stent with an initial assessment of major adverse cardiac events (MACE) at 30 days and a follow-up period of five years.


Related Links:
New Jersey Center for Biomaterials
Rutgers University
REVA Medical

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.